Figure 3

αCD22 Ab-MXD3 ASO conjugate shows significant in vivo dose-dependent therapeutic efficacy in Reh human leukemia mouse model. Kaplan-Meier survival curve for mice inoculated with Reh cells and treated with the αCD22 Ab-MXD3 ASO conjugate. Data from two independent experiments were combined (n = 4 or 8). In the first experiment, the mice were treated with PBS, free αCD22 Ab (1 mg/kg) plus free MXD3 ASO (0.8 mg/kg), and two different doses of the αCD22 Ab-MXD3 ASO conjugate (0.2 mg/kg or 1 mg/kg of the Ab). In the second experiment, the mice were treated with free αCD22 Ab (1, 5 or 10 mg/kg) plus free MXD3 ASO (0.8, 4 or 8 mg/kg), respectively, and three different doses of the αCD22 Ab-MXD3 ASO conjugate (1, 5 or 10 mg/kg of the Ab). PBS versus conjugate at any dose (0.2, 1, 5 or 10 mg/kg of the Ab) (**p < 0.01, ***p < 0.001, **p < 0.01 or **p < 0.01, respectively). Free αCD22 Ab (1 mg/kg) plus free MXD3 ASO (0.8 mg/kg) versus conjugate at any dose (0.2, 1, 5 or 10 mg/kg of the Ab) (**p < 0.01, ***p < 0.001, **p < 0.01 or **p < 0.01, respectively). Free Ab plus free ASO versus conjugate at the equivalent dose of the Ab (1, 5 or 10 mg/kg) (***p < 0.001, *p = 0.01 or **p < 0.01, respectively).